We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The latest opioid report from the office of Sen. Claire McCaskill (D-Mo.) delves into Insys Therapeutics’ sales policies for Subsys and concludes that the drugmaker used unethical methods to increase sales of its fentanyl product. Read More
Insurance giant Humana sued more than two dozen generic drugmakers in a federal court on Aug. 3 alleging they conspired to inflate prices for commonly used drugs. Read More
“The opioid crisis these pills have fueled is a failure of policy and oversight by the government and a failure … on the part of many pharmaceutical companies and distributors,” McCaskill said. Read More
In her third report on opioid abuse in the U.S., Sen. Claire McCaskill (D-Mo.) recommends giving the DEA more authority to penalize pharmaceutical distributors for failing to meet reporting obligations, and cites widely varying reporting numbers of big distributors as a sign of waning DEA enforcement. Read More
The FDA issued an alert Friday about a possible extortion scam targeting consumers, stating that imposters are issuing forged FDA warning letters to individuals who attempt to purchase medications online or over the phone. Read More
Other red flags the company ignored while continuing to make sales calls included a provider who responded to an investigation by changing the name of the practice, according to the lawsuit. Read More
A newly-unsealed lawsuit by the state of Tennessee alleges Purdue violated a 2007 settlement with the state and continued to use providers with histories of misconduct to provide its products. Read More